Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
40 participants
INTERVENTIONAL
2025-12-20
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
this group who undergoing iv contrast will receive hydration only
Hydration
before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml/h of normal saline
Amlodipine group
this group will receive hydration and amlodipine
Calcium channel blocker
amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour
Hydration
before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml/h of normal saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium channel blocker
amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour
Hydration
before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml/h of normal saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrew Samy Shafeek Shehata
Andrew Samy Shafeek
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Amlodipine role in CIN
Identifier Type: -
Identifier Source: org_study_id